INOVIO Presents Clinical Results of its DNA Medicines INO-5401...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pennsylvania Nov. 20, 2020 /PRNewswire-AsiaNet/ -- -- Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely...
Authors: LATEST ASIANET NEWS RELEASES